"The long-acting interleukin-2 drug failed to hit all three primary endpoints of the 783-patient trial in patients with previously untreated unresectable or metastatic melanoma, namely the objective response rate, progression-free survival and overall survival."

https://www.fiercebiotech.com/special-reports/2022s-top-10-clinical-trial-flops